Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance

Table 3 Patient characteristics – cancer

	*All*	*Possible*	*Probable*	*Definite*	P	*P (Pos vs Pro)*	*P (Pos vs Def)*	*P (Pro vs Def)*
Primary Cancer Type^a
Non-small cell lung cancer	5 (19)	1 (17)	1 (11)	3 (27)		0.999	0.999	0.591
Renal cell carcinoma	5 (19)	2 (33)	3 (33)	0		0.999	0.110	0.074
Melanoma	6 (23)	2 (33)	0	4 (36)		0.143	0.999	0.094
Other cancer	10 (38)	1 (17)	5 (56)	4 (36)		0.287	0.600	0.653
Prior Radiation^a
Chest radiation	4 (15)	0	2 (40)	2 (18)		0.486	0.515	0.999
Other radiation	11 (42)	3 (100)	3 (60)	5 (45)		0.622	0.999	0.670
Prior Treatment^a
Anthracyclines	2 (7)	0	2 (22)	0		0.486	0.999	0.190
VEGF inhibitors	7 (27)	4 (67)	3 (33)	0		0.315	0.0063	0.074
Other cancer treatment	14 (54)	2 (33)	4 (45)	8 (73)		0.999	0.162	0.362
ICI Therapy^a
Nivolumab (anti-PD-1)	8 (31)	3 (50)	2 (22)	3 (27)		0.329	0.600	0.999
Ipilimumab (anti-CTLA-4)	1 (4)	0	1 (11)	0		0.999	0.999	0.450
Pembrolizumab (anti-PD-1)	8 (31)	3 (50)	2 (22)	3 (27)		0.329	0.600	0.999
Atezolizumab (anti-PD-L1)	2 (7)	0	1 (11)	1 (9)		0.999	0.999	0.999
Combination therapy (Nivolumab + Ipilimumab)	7 (27)	0	3 (33)	4 (36)		0.229	0.237	0.999
Total ICI Cycles^a	9 ± 12	23 ± 17	4 ± 3	5 ± 4	0.0011	0.0223	0.0222	0.999
Cycle 1 to clinical diagnosis (mo)^a	9 ± 13	22 ± 14	8 ± 13	3 ± 3	0.0085	0.069	0.0071	0.997
Cycle 1 to death (mo)^b	16 ± 17	32 ± 20	6 ± 4	12 ± 12	0.0078	0.0085	0.0392	0.999
Clinical diagnosis to death (mo)^b	7 ± 10	10 ± 8	3 ± 3	9 ± 12	0.325
Deceased^a	22 (85)	6 (100)	7 (78)	9 (82)		0.486	0.515	0.999

Values are expressed as mean ± standard deviation or n (%). Fisher’s exact test was used when comparing categorical variables and Student’s t-test or analysis of variance when comparing continuous variables. P values < 0.05 were considered significant. The n are defined as the following for All, Possible, Probable, and Definite, respectively: ^an = 26, 6, 9, 11; ^bn = 22, 6, 7, 9. Possible, Probable, and Definite are based on the proposed reclassified myocarditis patient cohorts
CTLA-4 Cytotoxic T lymphocyte-associated protein 4, ICI Immune checkpoint inhibitors, mo months, PD-1 Programmed cell death protein 1, PD-L1 Programmed cell death ligand-1, VEGF Vascular endothelial growth factor

ISSN: 2057-3804